- Home
- VNT vs TLX Comparison
VNT vs TLX Comparison
Compare VNT & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNT
- TLX
- Stock Information
- Founded
- VNT 2019
- TLX 2015
- Country
- VNT United States
- TLX Australia
- Employees
- VNT N/A
- TLX N/A
- Industry
- VNT Industrial Machinery/Components
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- VNT Industrials
- TLX Health Care
- Exchange
- VNT Nasdaq
- TLX Nasdaq
- Market Cap
- VNT 5.4B
- TLX 5.7B
- IPO Year
- VNT N/A
- TLX N/A
- Fundamental
- Price
- VNT $38.21
- TLX $15.97
- Analyst Decision
- VNT Buy
- TLX Strong Buy
- Analyst Count
- VNT 7
- TLX 3
- Target Price
- VNT $44.20
- TLX $22.33
- AVG Volume (30 Days)
- VNT 867.9K
- TLX 52.5K
- Earning Date
- VNT 07-31-2025
- TLX 01-01-0001
- Dividend Yield
- VNT 0.26%
- TLX N/A
- EPS Growth
- VNT N/A
- TLX 798.14
- EPS
- VNT 2.46
- TLX 0.09
- Revenue
- VNT $2,964,300,000.00
- TLX $484,687,790.00
- Revenue This Year
- VNT $2.28
- TLX N/A
- Revenue Next Year
- VNT $5.05
- TLX N/A
- P/E Ratio
- VNT $15.57
- TLX $173.46
- Revenue Growth
- VNT N/A
- TLX 55.85
- 52 Week Low
- VNT $27.22
- TLX $13.61
- 52 Week High
- VNT $41.61
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- VNT 61.64
- TLX N/A
- Support Level
- VNT $37.76
- TLX N/A
- Resistance Level
- VNT $38.82
- TLX N/A
- Average True Range (ATR)
- VNT 0.66
- TLX 0.00
- MACD
- VNT 0.08
- TLX 0.00
- Stochastic Oscillator
- VNT 82.16
- TLX 0.00
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.